Hydreight Technologies Inc. Announces Strategic Investment in Insu Therapeutics to Advance Needle-Free Peptide Delivery Technology
Executive Summary
- Hydreight Technologies Inc. entered a subscription agreement to purchase 800,000 units of Insu Therapeutics Inc. for $300,000, representing a strategic investment in needle‑free peptide delivery technology.
- The consideration will be split equally between cash ($150,000) and Hydreight common shares (37,037 shares at $4.05 per share). Each unit includes one Insu share and one warrant to purchase an additional Insu share at $1.00 for two years.
- The investment positions Hydreight to potentially secure U.S. commercialization rights for buccal peptide products through its 50‑state telehealth and pharmacy network, subject to regulatory approvals and TSX Venture Exchange clearance.
Key Details
- Transaction Structure:
- 800,000 units @ $0.375 per unit = $300,000 total purchase price.
- Each unit = 1 Insu common share + 1 warrant (exercise price $1.00, 2‑year term).
-
Payment: 50% cash ($150,000) and 50% Hydreight common shares (37,037 shares at a deemed price of $4.05 per share).
-
Regulatory/Shareholder Approvals:
- Transaction pending TSX Venture Exchange approval.
-
No shareholder vote required under MI 61‑101 exemptions (valuation < 25% of market cap, no control change).
-
Strategic Rationale:
- Insu’s buccal delivery platform aims to enable needle‑free administration of complex peptides (e.g., insulin, GLP‑1 agonists) by delivering across the buccal mucosa, bypassing GI degradation.
-
Successful development could provide Hydreight with a differentiated, high‑margin product line and exclusive U.S. commercialization opportunities via its VSDHOne platform, telehealth network, and nationwide pharmacy infrastructure.
-
Insu Development Milestones:
- Completed Phase I in‑vitro release & pharmacokinetic studies for buccal semaglutide.
-
Received University of British Columbia Research Ethics Board approval to commence Phase II animal studies (pre‑clinical step before human trials).
-
Market Context:
- Global peptide therapeutics market > US$40 billion, growing at high single‑digit to low double‑digit rates.
-
Current delivery bottleneck: majority of peptide therapies are injection‑based; buccal platform could improve adherence and expand patient access.
-
Related Party Disclosure:
- Victory Square Technologies Inc. is a control person of both Hydreight and Insu; the transaction qualifies as a related‑party deal under TSX Venture Exchange policies, exempt from minority approval requirements.
Notable Quotes
-
Shane Madden, CEO, Hydreight Technologies:
“Hydreight is focused on building more than infrastructure – we are building long‑term strategic leverage through technology and product alignment. Insu's delivery approach represents the type of innovation that can potentially reshape how peptide‑based therapies are administered.”
-
Dr. Anubhav Pratap‑Singh, Scientific Advisor, Insu Therapeutics:
“If buccal delivery can consistently achieve systemic exposure profiles comparable to injectable formats, it has the potential to fundamentally change how complex peptide therapies are administered.”